Nitroso–Redox Balance in the Cardiovascular System

In this issue of the Journal, Taylor and colleagues report the results of the African-American Heart Failure Trial (A-HeFT), a double-blind, randomized trial that evaluated the effect of the addition of isosorbide dinitrate and hydralazine to the best conventional therapy in patients with symptomatic congestive heart failure who identified themselves as black. 1 The results with the combination therapy were markedly positive, meeting the composite end point of the trial, which included death from any cause, a first hospitalization for heart failure, and quality-of-life measures. In addition, there was an impressive reduction in the rate of death from any cause of . . .